Dr. Brar on the Rise of New Treatment Approaches in HCC

In Partnership With:

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Gagandeep Brar, MD, assistant professor of medicine, Division of Hematologic and Medical Oncology, Weill Cornell Medicine, discusses the rise of new treatment approaches in hepatocellular carcinoma (HCC).

Prior to 2017, HCC was a challenging ​disease to treat, and ​patients had fairly dismal prognos​es, Brar says.

However, over the past 3 years, a host of new data and research ​efforts have emerged, Brar adds.

Notably, in light of new treatment options, patients with HCC are now experiencing prolonged survival and improved quality of life​, explains Brar.

Ultimately, ​these developments have been encouraging in HCC and additional efforts are underway to further advance the paradigm, Brar concludes.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Experts on CRC
Related Content